Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.45 |
| ▸ | ARG1 | P05089 | 2/20 | 0.42 |
| ▸ | ARG2 | P78540 | 2/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760131 | 0.88 | KDM4E (0.39) | KCNA3CACNA1IKCNH2KDM4EALDH1A1 | |
| SCHEMBL13483418 | 0.88 | KDM4E (0.39) | KCNA3CACNA1IKCNH2KDM4EALDH1A1 | |
| SCHEMBL24278391 | 0.88 | SPHK1 (0.41) | KCNA3ARG1ARG2KDM4EALDH1A1 | |
| SCHEMBL12724660 | 0.88 | KDM4E (0.39) | KCNA3CACNA1IKCNH2KDM4EALDH1A1 | |
| SCHEMBL16247250 | 0.80 | CACNA1I (0.40) | CACNA1IKCNH2DPP4OPRM1OPRL1 | |
| SCHEMBL10032113 | 0.80 | CARM1 (0.52) | KCNA3CACNA1IKCNH2 | |
| SCHEMBL13101574 | 0.79 | CACNA1I (0.46) | ARG1ARG2CACNA1IKCNH2DPP4 | |
| SCHEMBL21983526 | 0.79 | ARG1 (0.40) | KCNA3ARG1ARG2CACNA1IKCNH2 | |
| SCHEMBL23919061 | 0.78 | CACNA1I (0.44) | CACNA1IKCNH2DPP4OPRM1OPRL1 | |
| SCHEMBL19959029 | 0.78 | CYP2D6 (0.40) | CACNA1IKCNH2DPP4OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-11759455-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-19 | — | — | US | disclosed |
| US-11759455-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-19 | — | — | US | disclosed |
| US-20230000833-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-01-05 | — | — | US | disclosed |
| US-20220098210-A1 | QUINDOLINE COMPOUNDS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-31 | — | — | US | disclosed |
| US-11207298-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-28 | — | — | US | disclosed |
| US-20210069155-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-11 | — | — | US | disclosed |
| US-20210002233-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10766865-B2 | PKM2 modulators and methods for their use | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-7666877-B2 | Ergoline derivatives | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20090018127-A1 | Ergoline Derivatives | NOVARTIS AG (CH) | 2009-01-15 | — | — | US | disclosed |
| US-20090018127-A1 | Ergoline Derivatives | NOVARTIS AG (CH) | 2009-01-15 | — | — | US | disclosed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-7351719-B2 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-04-01 | — | — | US | disclosed |
| US-7351719-B2 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-04-01 | — | — | US | disclosed |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207298-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | KCNA3 884/4885ARG1 3710/4885ARG2 2689/4885 |
| US-20090018127-A1 | Ergoline Derivatives | NR1H2, NR1H3, NR0B1 | KCNA3 1004/4885ARG1 470/4885ARG2 453/4885 |
| US-20220098210-A1 | QUINDOLINE COMPOUNDS AND USES THEREOF | RECQL, XPO7, XPOT | KCNA3 2968/4885ARG1 4882/4885ARG2 4561/4885 |
| US-10766865-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | KCNA3 472/4885ARG1 741/4885ARG2 341/4885 |
| US-20230000833-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | KCNA3 884/4885ARG1 3710/4885ARG2 2689/4885 |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | AURKA, AURKB, AURKC | KCNA3 1657/4885ARG1 2491/4885ARG2 2371/4885 |
| US-11759455-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | KCNA3 884/4885ARG1 3710/4885ARG2 2689/4885 |
| US-20210002233-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | KCNA3 472/4885ARG1 741/4885ARG2 341/4885 |
| US-20210069155-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | KCNA3 884/4885ARG1 3710/4885ARG2 2689/4885 |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | KCNA3 884/4885ARG1 3710/4885ARG2 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.